- Home
- SWBI vs MREO Comparison
SWBI vs MREO Comparison
Compare SWBI & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWBI
- MREO
- Stock Information
- Founded
- SWBI 1852
- MREO 2015
- Country
- SWBI United States
- MREO United Kingdom
- Employees
- SWBI N/A
- MREO N/A
- Industry
- SWBI Ordnance And Accessories
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- SWBI Industrials
- MREO Health Care
- Exchange
- SWBI Nasdaq
- MREO Nasdaq
- Market Cap
- SWBI 429.0M
- MREO 438.8M
- IPO Year
- SWBI N/A
- MREO N/A
- Fundamental
- Price
- SWBI $8.54
- MREO $1.66
- Analyst Decision
- SWBI Buy
- MREO Strong Buy
- Analyst Count
- SWBI 2
- MREO 5
- Target Price
- SWBI $12.00
- MREO $7.20
- AVG Volume (30 Days)
- SWBI 1.3M
- MREO 3.5M
- Earning Date
- SWBI 09-04-2025
- MREO 08-12-2025
- Dividend Yield
- SWBI 6.09%
- MREO N/A
- EPS Growth
- SWBI N/A
- MREO N/A
- EPS
- SWBI 0.30
- MREO N/A
- Revenue
- SWBI $474,661,000.00
- MREO N/A
- Revenue This Year
- SWBI $8.53
- MREO N/A
- Revenue Next Year
- SWBI N/A
- MREO $52.34
- P/E Ratio
- SWBI $28.47
- MREO N/A
- Revenue Growth
- SWBI N/A
- MREO N/A
- 52 Week Low
- SWBI $8.38
- MREO $1.58
- 52 Week High
- SWBI $16.85
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- SWBI 36.14
- MREO 29.70
- Support Level
- SWBI $8.53
- MREO $2.77
- Resistance Level
- SWBI $8.85
- MREO $3.05
- Average True Range (ATR)
- SWBI 0.23
- MREO 0.18
- MACD
- SWBI -0.04
- MREO -0.06
- Stochastic Oscillator
- SWBI 20.54
- MREO 9.76
About SWBI Smith & Wesson Brands Inc.
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).